Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options

Basit Öğe Kaydı
dc.contributor.authorAgcaoglu O.
dc.contributor.authorSezer A.
dc.contributor.authorMakay O.
dc.contributor.authorErdogan M.F.
dc.contributor.authorBayram F.
dc.contributor.authorGuldiken S.
dc.contributor.authorMihai R.
dc.date.accessioned2021-05-03T20:59:05Z
dc.date.available2021-05-03T20:59:05Z
dc.date.issued2021
dc.description.abstractPurpose: The COVID-19 pandemic brought unprecedented conditions for overall health care systems by restricting resources for non-COVID-19 patients. As the burden of the disease escalates, routine elective surgeries are being cancelled. The aim of this paper was to provide a guideline for management of endocrine surgical disorders during a pandemic. Methods: We used Delphi method with a nine-scale Likert scale on two rounds of voting involving 64 experienced eminent surgeons and endocrinologists who had the necessary experience to provide insight on endocrine disorder management. All voting was done by email using a standard questionnaire. Results: Overall, 37 recommendations were voted on. In two rounds, all recommendations reached an agreement and were either endorsed or rejected. Endorsed statements include dietary change in primary hyperparathyroidism, Cinacalcet treatment in secondary hyperparathyroidism, alpha-blocker administration for pheochromocytoma, methimazole ± ?-blocker combination for Graves’ disease, and follow-up for fine-needle aspiration results of thyroid nodules indicated as Bethesda 3–4 cytological results and papillary microcarcinoma. Conclusion: This survey summarizes expert opinion for the management of endocrine surgical conditions during unprecedented times when access to surgical treatment is severely disrupted. The statements are not applicable in circumstances in which surgical treatment is possible. © 2021, Italian Society of Surgery (SIC).en_US
dc.identifier.doi10.1007/s13304-021-00979-8
dc.identifier.issn2038-131X
dc.identifier.issn2038-131Xen_US
dc.identifier.pmid33840069en_US
dc.identifier.scopus2-s2.0-85104137941en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s13304-021-00979-8
dc.identifier.urihttps://hdl.handle.net/11454/71593
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.relation.ispartofUpdates in Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConsensusen_US
dc.subjectEndocrine diseaseen_US
dc.subjectExpert opinionen_US
dc.subjectPandemicen_US
dc.subjectQualtricsen_US
dc.subjectSurveyen_US
dc.titleManagement of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical optionsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu